Mark A Michaels

US Patent:

20130225484, Aug 29, 2013

Filed:

Feb 25, 2013

Appl. No.:

13/775756

Inventors:

Mark Leo Michaels - Encino CA, US
Thomas C. Boone - Newbury Park CA, US
Rohini Deshpande - Camarillo CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Huiquan Han - Thousand Oaks CA, US

Assignee:

AMGEN - Thousand Oaks CA

International Classification:

C07K 14/71

US Classification:

514 48, 530350, 5303873, 536 235, 4353201, 435325, 435 691, 514 212, 514 154, 514 166, 514 69, 514 167

Abstract:

The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

US Patent:

40794890, Mar 21, 1978

Filed:

Dec 30, 1976

Appl. No.:

5/755524

Inventors:

John Lawrence Kowalski - Phoenix AZ
Mark Joseph Michaels - Glendale AZ
Edmund Harold Schieve - Phoenix AZ

Assignee:

Honeywell Information Systems Inc. - Phoenix AZ

International Classification:

H05K 1304
H01L 2172

US Classification:

29 33K

Abstract:

A machine for blanking an integrated circuit chip from a segment of a film strip held in a fixture, forming its leads, and placing the chip on a multilayer substrate. The fixtures are stacked in a magazine which is mounted on the machine. A transfer mechanism transfers one fixture at a time from the magazine to a punch press where the IC chip is blanked from its film segment, and its leads are formed. The punch is retracted, and a multilayer substrate, which is mounted on an X-Y table, is positioned by the table under the punch so that the excised chip is directly above a chip pad and the chip leads are above the chip lead pads of a predetermined chip pad. The punch is lowered to position the chip on its chip pad. The substrate is coated with an adhesive flux to retain the chips and their leads in place. The punch is retracted and the X-Y table is moved to clear the punch press.

US Patent:

40843157, Apr 18, 1978

Filed:

Dec 30, 1976

Appl. No.:

5/755525

Inventors:

Mark Joseph Michaels - Glendale AZ

Assignee:

Honeywell Information Systems Inc. - Phoenix AZ

International Classification:

H01L 2160

US Classification:

29740

Abstract:

A fixture for use in soldering a large number of integrated circuit (IC) chips to a multilayer substrate in a single reflow soldering operation. A multilayer substrate with IC chips and their leads properly positioned on the substrate is placed within the base of the fixture. The force structure portion of the fixture is positioned on the base so that force pins, which are movable with respect to the force structure, can be lowered, or moved toward the substrate to apply the weight of a force pin to each IC chip to be soldered to the substrate. The weight, or force, of a force pin forces the back metal layer of each IC chip and its leads against a chip pad and chip lead pads of the substrate. The substrate is heated to melt, or to reflow, the solder on all the chip pads and chip lead pads. After the leads and back metal layer of each chip are wetted by the solder and while the solder is molten, the force structure is moved away from the base to remove the weight of the force pins from the IC chips.

US Patent:

60968656, Aug 1, 2000

Filed:

May 6, 1996

Appl. No.:

8/643704

Inventors:

Mark Michaels - Encino CA

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 14435
C12N 1511
C12N 510

US Classification:

530350

Abstract:

The present invention relates to mutants of the green fluorescent protein having improved fluorescent properties at 37. degree. C. The mutants provide for improved methods of monitoring gene expression, e. g. , for use as cell markers or protein expression indicators in prokaryotic and, especially, eucaryotic systems where the standard physiological temperature is 37. degree. C.

US Patent:

20220402985, Dec 22, 2022

Filed:

Jun 9, 2022

Appl. No.:

17/836425

Inventors:

- Thousand Oaks CA, US
Zhi LIU - Shoreline WA, US
TaeWeon LEE - Palo Alto CA, US
Mark L. MICHAELS - Encino CA, US
Zhulun WANG - Palo Alto CA, US

International Classification:

C07K 14/485
A61P 9/10

Abstract:

The present invention relates to engineered neuregulin-1 variants that selectively activate ErbB4 receptors but do not activate ErbB3 receptors. The invention also provides methods for using such variants to treat heart failure.

US Patent:

20220195022, Jun 23, 2022

Filed:

Dec 21, 2021

Appl. No.:

17/558032

Inventors:

- Thousand Oaks CA, US
Irwin CHEN - Los Angeles CA, US
Su CHONG - Oxnard CA, US
Bryna FUCHSLOCHER - Thousand Oaks CA, US
Kevin GRAHAM - Thousand Oaks CA, US
Agnes Eva HAMBURGER - Newbury Park CA, US
Mark Leo MICHAELS - Encino CA, US
Christopher MOHR - Newbury Park CA, US
Derek E. PIPER - Santa Clara CA, US
Kenneth William WALKER - Newbury Park CA, US
Zhulun WANG - Los Altos CA, US
Cen XU - Newbury Park CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/18
C07K 16/28
A61P 25/06
A61K 38/22

Abstract:

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

US Patent:

20230077648, Mar 16, 2023

Filed:

Apr 18, 2022

Appl. No.:

17/722724

Inventors:

- Thousand Oaks CA, US
Martin J. Pentony - Seattle WA, US
Luis G. Borges - Redwood City CA, US
Mark L. Michaels - Encino CA, US

International Classification:

C07K 16/46
C07K 16/30
C07K 16/28
C07K 16/32

Abstract:

Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.

US Patent:

20210017261, Jan 21, 2021

Filed:

Jul 1, 2020

Appl. No.:

16/919032

Inventors:

- Thousand Oaks CA, US
Irwin CHEN - Los Angeles CA, US
Su CHONG - Oxnard CA, US
Bryna FUCHSLOCHER - Thousand Oaks CA, US
Kevin GRAHAM - Thousand Oaks CA, US
Agnes Eva HAMBURGER - Newbury Park CA, US
Mark Leo MICHAELS - Encino CA, US
Christopher MOHR - Newbury Park CA, US
Derek E. PIPER - Santa Clara CA, US
Kenneth William WALKER - Newbury Park CA, US
Zhulun WANG - Palo Alto CA, US
Cen XU - Newbury Park CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/18
C07K 16/28
A61P 25/06
A61K 38/22

Abstract:

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.